FDA APPROVES QUTENZA(TM), FIRST AND ONLY PRESCRIPTION STRENGTH CAPSAICIN PRODUCT FOR PAIN REDUCTION
The U.S. Food and Drug Administration (FDA) has approved Qutenza, a new
prescription patch applied to the skin for one hour for reduction of
post-shingles nerve pain. Qutenza is the first and only prescription strength
capsaicin product. Qutenza contains a manmade form of capsaicin, the
substance in chili peppers that gives them their heat sensation.
After a single one-hour application, directly to the site of pain,
Qutenza may reduce post shingles nerve pain for up to 12 weeks. Qutenza is
applied by a doctor or healthcare professional. Qutenza can be used alone or
with other pain medications and is unlikely to cause drug-drug interactions.
* Each year, about a million Americans develop shingles, a painful virus
infection related to chicken pox.
* Up to one in five people with shingles will experience prolonged pain
due to a complication called postherpetic neuralgia (PHN).
o PHN is a chronic condition that is the result of nerve damage caused by
the shingles virus.
o The pain can persist long after the characteristic rash clears up and
can disrupt sleep, mood, work and activities of daily living.
o The risk of developing PHN increases with age, especially in people
over 50, and for patients who experienced severe pain or severe rash during
the acute shingles episode.
Please see full prescribing information at www.qutenza.com. SATELLITE FEEDS: Monday, November 16th, 2009 Tuesday, November 17th, 2009 7:30 PM - 7:45 PM ET 3:00 AM - 3:15 AM ET Galaxy 19 Galaxy 19 C-Band C-Band Transponder 20 Transponder 20 Downlink Freq. 4100 Horizontal Downlink Freq. 4100 Horizontal Tuesday, November 17th, 2009 1:00 PM - 1:15 PM ET AMC 3 C-Band Transponder 3 Downlink Freq. 3760 Horizontal
NEWS: FDA Approves Qutenza, the first and only prescription strength
treatment with capsaicin, the “hot ingredient in chili peppers. Qutenza can
provide 12 Weeks of pain reduction from a single one hour treatment for
FORMAT: B-roll and Soundbites
ADDITIONAL RESOURCES: Video, contact information and more available at:
SOUNDBITES: * Tony DiTonno - Chief Executive Officer, NeurogesX, Inc. * Lynn R. Webster, M.D., F.A.C.P.M., F.A.S.A.M. - Medical Director, Lifetree Clinical Research, Salt Lake City, Utah B-ROLL INCLUDES: * Doctor and patient in examination room * Product shot * Process for application and removing of dermal system * Chili peppers * Product and Company logos
VIDEO PROVIDED BY: NeurogesX
Contact: FOR MORE INFORMATION, PLEASE CALL: MultiVu Media Relations,
1-800-653-5313 EXT. 3